Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and ...

Tirzepatide is more cost-effective than semaglutide for knee osteoarthritis and obesity, optimizing resources for patients not seeking surgical options, which remain cost-effective for those eligible.